Collection of population-based cancer staging information in Western Australia – a feasibility study by Threlfall, Timothy et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Population Health Metrics
Open Access Research
Collection of population-based cancer staging information in 
Western Australia – a feasibility study
Timothy Threlfall*1, Jana Wittorff1, Padabphet Boutdara1, Jane Heyworth2, 
Paul Katris3, Harry Sheiner3 and Lin Fritschi2
Address: 1Western Australian Cancer Registry, Department of Health, Government of Western Australia, Perth, Australia, 2School of Population 
Health, University of Western Australia, Perth, Australia and 3Western Australian Clinical Oncology Group, The Cancer Council of Western 
Australia, Perth, Australia
Email: Timothy Threlfall* - tim.threlfall@health.wa.gov.au; Jana Wittorff - janaw@ferriscan.com; 
Padabphet Boutdara - padabphet@hotmail.com; Jane Heyworth - jane.heyworth@uwa.edu.au; Paul Katris - pkatris@cancerwa.asn.au; 
Harry Sheiner - wacog@cancerwa.asn.au; Lin Fritschi - lfritschi@qldcancer.com.au
* Corresponding author    
Abstract
Background: Routine data from cancer registries often lack information on stage of cancer, limiting their use.
This study aimed to determine whether or not it is feasible to add cancer staging data to the routine data
collections of a population-based Western Australian Cancer Registry (WACR).
Methods: For each of the five most common cancer types (prostate, colorectal, melanoma, breast and lung
cancers), 60 cases were selected for staging. For the 15 next most common cancer types, 20 cases were selected.
Four sources for collecting staging data were used in the following order: the WACR, the hospital based cancer
registries (HBCRs), hospital medical records, and letters to treating doctors. If the case was unable to be fully
staged, due to lack of information on regional lymph node invasion or distant metastases, we made the following
assumptions. Cases which had data available for tumour (T) and regional lymph nodes (N), but no assessment of
distant metastasis (MX) were assumed to have no distant metastases (M0). Cases which had data for T and M,
but no assessment of regional nodal involvement (NX) were assumed to have no regional nodal involvement (N0).
Results: The main focus of this project was the process of collecting staging data, and not the outcomes. For
ovary, cervix and uterus cancers the existence of a HBCR increased the stageable proportion of cases so that
staging data for these cancers could be incorporated into the WACR immediately. Breast and colorectal cancer
could also be staged with adequate completeness if it were assumed that MX = M0. Similarly, melanoma and
prostate cancer could be staged adequately if it were assumed that NX = N0 and MX = M0. Some cases of
stomach, lung, pancreas, thyroid, testis and kidney cancers could be staged, but additional clinical input – on
pathology request forms, for example – would be required to achieve useable levels of completeness. For the
remaining cancer types either staging is widely regarded as not relevant, and no generally-accepted system exists,
or an acceptable level of completeness is not achievable.
Conclusion: Adding stage to routinely collected information in a cancer registry is possible for many cancer
types, particularly if the assumptions regarding missing data are found to be acceptable or if the guidelines for MX
= M0 asumptions are clarified. These findings should be generalizable to most cancer registries in developed
countries, if hospital-based cancer registries or other specialized databases are accessible.
Published: 17 August 2005
Population Health Metrics 2005, 3:9 doi:10.1186/1478-7954-3-9
Received: 28 June 2005
Accepted: 17 August 2005
This article is available from: http://www.pophealthmetrics.com/content/3/1/9
© 2005 Threlfall et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Population Health Metrics 2005, 3:9 http://www.pophealthmetrics.com/content/3/1/9
Page 2 of 6
(page number not for citation purposes)
Background
Cancer staging information is of fundamental importance
at both population and individual levels. For the individ-
ual, it facilitates provision of appropriate patient care,
enables appropriate selection of treatment for individual
cases, can be used to explain variability in treatment out-
comes, and can contribute to helping an individual
patient and their family to better understand the clinical
condition and prognosis. At the population level, staging
data can guide the development and evaluation of health
promotion and treatment programs, can facilitate more
effective resource allocation depending on the relative
proportions of "early" as opposed to "late" cases and can
be used to stratify survival analyses to improve compari-
son of results of different groups such as geographic areas
[1-3]. The lack of staging data has been recognised by cli-
nicians and public health professionals alike as an impor-
tant limitation of cancer registry data.
Different staging systems exist and they have different
rules and guidelines. Commonly used staging systems
include those of the American Joint Committee on Cancer
(AJCC), International Union Against Cancer (UICC) and
International Federation of Gynaecology and Obstetrics
(FIGO) which all rely upon characteristics of primary
tumour, nodes and metastases as a basis. The Ann Arbor
and Dukes classifications also use similar definitions and
principles [4,5].
The TNM system depends on the combination of different
characteristics of the tumour. T describes the primary
tumour size and/or extent, N describes the presence or
absence of regional lymph node metastasis and M
describes the presence or absence of distant metastasis.
Each of these components is divided into numerical sub-
sets (T0 – T4, N0 – N3, M0 – M1) which describe how
advanced the malignancy is. The definitions of these sub-
sets are specific for each tumour and are delineated in a
handbook [4]. Depending on the specific combination of
T, N and M, an individual cancer will be assigned to a
"stage".
For most cancers, the staging of the tumour depends only
on TNM. However, some tumours also require additional
information for staging (for example, serum tumour
markers for testicular cancer) [4]. Additional prognostic
factors may be increasingly included in the delineation of
the TNM stage grouping. The TNM system is flexible and
accepted worldwide for patient care, and has been vali-
dated as being relevant to the clinical practice of oncology
[6].
Western Australia is the largest state of Australia. With an
area of more than 2 500 000 sq km, a 12 500 km coastline
and spanning 2 400 km from north to south, it occupies a
third of the continent. The total population of Western
Australia is just under 1.5 million people of whom 1.2
million live in and around the capital city of Perth.
The Western Australian Cancer Registry (WACR) is a pop-
ulation-based cancer registry, which was established in
1981, based on the mandatory reporting of cancers by
pathologists, haematologists and radiation oncologists
[7]. The WACR routinely collects data relating to tumour
location, type, basis and date of diagnosis, and grade,
together with demographic information and some possi-
ble sources of further information. At present the WACR
does not routinely register information on cancer stage.
Recognising the need for these data, this project aimed to
determine the feasibility, in terms of ascertainment and
effort required, of adding staging data to the WACR.
There are four major public hospitals in Perth and three
major private hospitals. Each of the public hospitals has a
Hospital Based Cancer Registry (HBCR) which collects
information on a limited range of cancer types, including
information on staging at the time of diagnosis.
Methods
The project aimed to collect staging data on a selection of
cancer cases from among those notified to the WACR,
including cases notified in the past (retrospective data col-
lection) and in the present (prospective data collection).
The retrospective cases were those diagnosed in 1998
(300) and in January – June 2002 (150); the prospective
cases (150) were those diagnosed after June 2002. The
cancer types were selected on the basis of the 20 most
common incident cancers in 2000 (apart from non-
melanocytic skin cancers, which are not collected by
WACR). For each of the five most common cancer types
(prostate, colorectal, melanoma, breast and lung cancers)
60 cases were randomly selected for staging and for the
remaining 15 cancer types, 20 cases were selected.
Approval for access to medical records was requested from
each hospital in which selected cases had been treated.
There were 4 sources for collecting data for the staging: the
WACR, the HBCRs, hospital medical records, and
responses to enquiry letters to treating doctors. For most
cancers, this was the order in which the sources were
approached. The first step involved reviewing the WACR
files and extracting available staging data from pathology
reports. If the cancer could not be fully staged from the
WACR files, the HBCRs were approached for any staging
information they held. If full staging information was not
available from WACR or HBCRs, a project officer reviewed
casenotes at both private and public hospitals. For reasons
related to costs, medical records were not searched at
country hospitals and small city hospitals. If the cancerPopulation Health Metrics 2005, 3:9 http://www.pophealthmetrics.com/content/3/1/9
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was still unable to be staged, a letter was sent to the treat-
ing clinician requesting staging information.
For some cancers, specific local circumstances meant it
was more efficient to undertake the steps in a different
order, or to omit some steps. Gynaecological cancers (cer-
vix, uterus and ovary), are to a large extent treated in one
public hospital with an active HBCR. The FIGO summary
stage for all gynaecological cancers was generally the only
information used for these cancers. For colorectal cancer,
information was obtained initially from the HBCRs and
also obtained from the WA Research Tissue Network,
which collects statewide data (including stage) on certain
cancers. Cases which could not be staged using these
resources were then researched using other sources as nec-
essary. For the lymphohaematopoietic malignancies, for
which the TNM system is not appropriate, and for brain
cancers, WACR files only were reviewed. For melanoma,
most cases do not require hospital admission so HBCRs
and hospital casenote reviews were not done.
It should be noted that the stage at diagnosis commonly
includes data collected over a period of up to 4 months [8]
although the WACR uses 3 months as a routine.
We calculated the proportion of cases that could be staged
after each step of the staging process overall and stratified
by prospective and retrospective groupings.
In order to definitively stage many cancers, considerable
clinical investigation is required. For example, lymph
nodes need to have been dissected or biopsied, or exten-
sive searches for metastases need to have been under-
taken. These further investigations have associated costs
and risks and may not always be clinically warranted. For
example, if a melanoma is found to be level 1, and there
is no clinical evidence of spread, investigations such as
chest X-rays and bone scans are unlikely to be performed.
In addition, some cases do undergo further investigations
but the results are held in private rooms, or medical
records do not contain any negative information such as
the absence of metastases. In addition, doctors may not
have responded to our letters asking for information on
stage. For many of the cases in this study, therefore, it was
not possible to stage the cancer definitively because of the
lack of information on regional nodal status or the pres-
ence or absence of distant metastases. Many of these cases
are most likely to be early stage cancers.
The data for those cases that were not stageable were fur-
ther examined, and two different assumptions were
applied. The first assumption was applied to cases which
had data for T and N but which had no assessment of dis-
tant metastasis (MX). The assumption made was that MX
was equivalent to M0 (no distant metastases). This is sum-
marized as MX = M0 in the tables.
The second assumption was applied to cases with data for
T and M, but with no assessment of regional nodal
involvement (NX). The assumption made was that NX
was equivalent to N0 (no regional nodal involvement).
This is summarized as NX = N0 in the tables.
The number of cases that could be staged if both assump-
tions were made for the same case (ie NX = N0 and MX =
M0) was also calculated. All original data (without
assumptions) was stored separately.
The costs of collecting staging data were also estimated.
For each cancer type, actual times from the study were
extrapolated to costs based on a whole year's collection of
staging data. Tasks contributing to this time included:
reviewing pathology reports; looking at electronic files at
WACR; examining medical case notes; writing enquiry let-
ters and reviewing replies. Added to this were general costs
including travel, liaison with data holders, training, leave,
general office duties, and delays due to competing priori-
ties of hospital and other non-WACR staff.
Results
The focus of this project was the process of collecting stag-
ing data, and not the actual stages of the cancers.
The main finding from this feasibility study is that staging
completeness is very dependent on cancer type (Table 1).
Each type has its own issues and complications. However,
in order to summarize the results we have grouped some
types together as follows:
• Group A: cancers for which virtually complete staging
data could be obtained relatively easily. Relatively com-
plete information on stage of these cancers was available
with current systems.
• Group B: cancers for which relatively high proportions
of cancers could be fully staged, and for which the
assumption MX = M0 allows almost complete staging. If it
was considered reasonable to apply this assumption, rela-
tively complete information on stage would be available
on these cancers.
• Group C; cancers which can almost all be staged making
the assumptions NX = N0 and MX = M0. If it was consid-
ered reasonable to apply these assumptions, relatively
complete staging information could be collected.
• Group D; cancers for which it is more risky to apply the
assumptions. Accurate collection requires system changes
in order to obtain better information on stage.Population Health Metrics 2005, 3:9 http://www.pophealthmetrics.com/content/3/1/9
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• Group E; cancers for which staging is not feasible at
present.
Group A cancers (Table 1) consisted of the gynaecological
cancers: ovary, cervix and uterus. The use of the HBCR at
the gynaecological hospital was clearly crucial for staging
these cancers, increasing the stageable proportion of cases
from 60% to 100% for ovarian cancer and from 16% to
95% for cervical cancer. For these cancers there was no
need to apply any assumptions. Relatively complete stag-
ing data could be collected easily.
Group B cancers consisted of breast and colorectal cancer.
For these two cancers, a reasonable number of cases could
be staged fully using the standard 4 steps. For colorectal
cancer, 80% of cases could be staged after all four steps
were completed, with this increasing to 92% if the
assumption MX = M0 was applied. For breast cancer 65%
of the cases could be staged after all four steps were com-
pleted, increasing to 95% when applying the assumption
MX = M0.
Group C cancers consisted of melanoma and prostate
cancer. Only 34% of prostate cancer cases and 0% of
melanoma cases could be staged using only the WACR,
mainly because of lack of information on nodal status and
metastases. However, if both assumptions of NX = N0 and
MX = M0 were applied this increased to 100% of prostate
cancers and 97% of melanomas.
Group D cancers include cancers of the stomach, lung,
pancreas, thyroid, testis and kidney. Cancer types in
Group D would require additional clinical input to
achieve adequate proportions of staged cancers. Making
Table 1: Percentage of cases staged, by cancer type and process used. Percentages shown are cumulative, beginning from the left.
Cancer type Staged from WACR 
data alone (%)
Staged from WACR 
and HBCRs, WARTN 
(%)
Staged after all 
completed steps (no 
assumptions) (%)
Staged after all steps 
with assumption/s (%)
Group A: Could be staged now
Ovary 60^ 100 100 100
Cervix 16^ 95 100 100
U t e r u s 5 0 ^ 8 59 59 5
Group B: Could be staged now, making MX = M0 assumption
B r e a s t 0 1 26 59 5
Colorectal 12^ 53 80 92
Group C: Could be staged now, with NX = N0 and MX = M0 assumptions
Melanoma 0 (0) 57 100
Prostate 2 5 34 97
Group D: Could be started now with MX = M0, but long term collection requires system changes
S t o m a c h * * 2 52 57 09 5
Lung 18 38 76 86
Pancreas 45 45 70 80
T h y r o i d * * 1 01 04 77 9
Testis** 10 10 75 75
Kidney** 15 20 65 70
Group E: Staging not feasible at present
Oesophagus** 0 0 50 65
Bladder** 0 0 40 55
Lip 0 (0) 37 42
Lymphoma 44 (44) 44 44
Myeloma 0 (0) 0 0
Leukaemia 0 (0) 0 0
Brain 0 (0) 0 0
^ These numbers could have been higher as the external databases were searched first, and WACR later searched only for incomplete cases.
** Only one HBCR currently collects data on these cancers except bladder, for which two HBCRs are collecting data.
() Numbers in parentheses indicate that the additional data source/s indicated by the column header, was/were not accessed as they were either 
not applicable to the cancer type, or research suggested the additional effort would be unrewarding.Population Health Metrics 2005, 3:9 http://www.pophealthmetrics.com/content/3/1/9
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the assumption of MX = M0, a relatively high proportion
of cases may be able to be staged. However, the accepta-
bility of the assumptions differs among cancers.
Cancer types in Group E are not able to be staged at
present. After all four steps were completed only 50%,
40% and 37% of cases could be staged, for cancers of the
oesophagus bladder and lip, respectively. These levels of
completeness were still inadequate even after applying the
assumption MX = M0. No myeloma or leukaemia cases
could be staged at only step 1, and the only lymphoma
cases that could be staged were Stage 4. The amount of
clinical information required to stage these cancers goes
far beyond the pathological details available. There is no
accepted staging system for brain cancer.
Costs were estimated assuming that the HBCRs continued
to operate. In this case, collection of staging data on
Group A cancers would cost approximately 0.1 of a full-
time equivalent staff member. Costs of collecting staging
data for Groups A and B would require about one half-
time staff member and to collect staging data on Groups
A, B and C would require about one full-time staff mem-
ber. This is in relation to a population of 1.5 million.
Discussion
The main finding from this study is that collection of ade-
quate staging data by population-based cancer registries
depends primarily on the type of cancer and the existence
of HBCRs or other specialized registries which already col-
lect such data. Because HBCRs already collect high quality
staging information in Western Australia, their operation
is vital to the efficiency and cost-effectiveness of popula-
tion-based collection of staging data. As can be seen from
the results of this study, in cases where HBCRs covered a
large proportion of the cancers seen in WA (for example
the gynaecological cancers, or colorectal cancer), the pro-
portion of cases which could be staged was high. In other
cases, such as melanoma, for which no HBCR collects
staging information, the proportion of cases which could
be staged tended to be low. The greater the coverage of
HBCRs in terms of cancer types and hospitals, the better
the stage collection of the population-based registry can
be. While this is cost-efficient for the population based
registry, costs have to be borne by the HBCRs.
In this study, we had a short timeline which meant that
the data we were able to access from the HBCRs was prob-
ably less complete than would be available over a longer
period. On the other hand, the fact that we did not collect
information from small country hospitals means that we
probably slightly overestimated the proportion of cancers
which could be staged.
One of the problems in attempting to collect staging data
for a variety of different cancer types was that population-
based cancer registries such as the WACR usually rely on
pathology reports, and do not routinely receive non-
pathology reports. These include radiological reports such
as CT scans, X-rays and PET scans which contain informa-
tion on N and M. Other information not routinely sup-
plied to registries may be crucial to staging, such as
hormonal assays for testicular cancer, negative lymph
node biopsies for breast cancer, and haemoglobin level
and cell counts in leukaemia.
Related to this was the necessity to make assumptions
about MX and NX. The acceptability of these assumptions
needs to be ascertained and is different for the different
cancer sites. For example, for melanomas of Clark level I
[9], or low Breslow thickness [10], it is probably quite rea-
sonable to assume that NX = N0 and MX = M0. However,
for stomach and pancreatic cancer, the viability of the MX
= M0 assumption is questionable as these cancers are
often at a late stage when diagnosed. This means that can-
cer sites which had similar proportions of stageable can-
cers without assumptions were placed in different
categories depending on how clinical acceptable the
assumptions were. For example, only 54% of the melano-
mas could be staged without assumptions, and 100%
with assumptions and clinically it was thought that the
assumptions were reasonable. However, 70% of the stom-
ach cancers could be staged without assumptions, and
95% with assumptions but clinically it was not thought
that the assumptions were reasonable.
Where it is not thought appropriate to apply the MX = M0
assumption to all unstaged cancer cases, an alternative
strategy would be to work with clinicians in order to
develop rules about for which cases it would be appropri-
ate to apply this assumption. A separate study suggests
that it is safe to make the MX = M0 assumption in 90% of
breast cancer cases with T1, T2 or T3 and either N0 or N1
(personal communication, Padabphet Boutdara) and
about 85% of similar colorectal cancer cases [11].
A more difficult problem occurred when the cancer was
diagnosed on a biopsy specimen. In these cases, even the
information on tumour size (T) was often unable to be
ascertained.
Increasing the proportion of cancers which could be
staged would require a greater level of input from clini-
cians than currently exists. For instance, the use of synop-
tic structured pathology reports would assist the staging of
these cancers, by providing a consistent approach to stag-
ing, as well as an easy format for the clinicians to provide
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In order to guide our comments on the feasibility of vari-
ous potential recommendations we interviewed specialist
clinicians interested in specific cancer types, to canvass
their views on issues relating to staging data collection.
Some of the issues raised by clinicians were confidential-
ity and privacy concerns, and access to and "ownership"
of data. In addition, there was disagreement among the
clinicians as to whether it was the responsibility of clini-
cians to do the staging, or whether that should be done by
registry staff.
There are several other problems with adding staging to a
population based registry. If a formal screening program
is introduced there may be better recording of data and
less missing information on stage over time. In addition it
is important to consider whether staging in a population-
based cancer registry is worthwhile if reasonable levels of
completeness cannot be achieved. For example, it may be
hard to justify collection of data for kidney, testicular, thy-
roid or pancreatic cancer as 20% – 30% of cases in a sta-
tistical analysis would not have staging information.
Conclusion
Adding stage to a population-based cancer registry is
highly dependent on the type of the cancer. However, rou-
tinely collected staging is possible for many cancer types
with the co-operation of HBCRs and the assumptions of
negative nodal or metastatic status for some types. These
findings should be generalizable to most cancer registries
in developed countries, if hospital-based cancer registries
or other specialized databases are accessible.
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